ARIA ARIAD Pharmaceuticals, Inc.

ARIAD to Present at the Jefferies 2016 London Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 London Healthcare Conference. Company management will provide an overview of the Company’s business on Wednesday, November 16, 2016 at 4:40 p.m. (GMT).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the site for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

EN
02/11/2016

Underlying

ARIAARIAD Pharmaceuticals, Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ARIAD Pharmaceuticals, Inc.

MarketLine Department
  • MarketLine Department
EUR 299.39
GLYC GlycoMimetics ...
GILD Gilead Sciences... ... (+4)

Kalobios Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partner...

Summary Marketline's Kalobios Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Kalobios Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive ...

GLYC GLYCOMIMETICS INC.
GILD GILEAD SCIENCES INC.
ARIA ARIAD PHARMACEUTICALS
INC.
10/29/20 October 29, 2020 158 EN
MarketLine Department
  • MarketLine Department
EUR 311.72
ARIA ARIAD Pharmaceu...

ARIAD Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partners...

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights United States

ARIA ARIAD PHARMACEUTICALS
INC.
06/14/17 June 14, 2017 78 EN
 PRESS RELEASE
Free
ARIA ARIAD Pharmaceu...
INC.

ARIAD Announces Submission of Marketing Authorization Application for ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines Agency (EMA). ARIAD is seeking marketing approval in the European Union of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been previously treated with crizotinib. The U.S. Food and Drug Administration...

February 6, 2017 1 EN
 PRESS RELEASE
Free
ARIA ARIAD Pharmaceu...
INC.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) (“ARIAD” or the “Company”) relating to the proposed buyout of ARIAD by Takeda Pharmaceutical Company Limited. Under the terms of the agreement, ARIAD shareholders are anticipated to receive $24.00 in cash for each share of ARIAD common sto...

January 13, 2017 1 EN
 PRESS RELEASE
Free
ARIA ARIAD Pharmaceu...
INC.

ARIAD PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of ARIAD Pharmaceuticals, Inc. (NASDAQ GS: ARIA)? Did you purchase any of your shares prior to January 9, 2017? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ...

January 9, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch